Armata Pharmaceuticals Inc (ARMP)
NYSE MKT:ARMP

Armata Pharmaceuticals (ARMP) Income Statement

249 Followers

Armata Pharmaceuticals Income Statement

Last quarter (Q1 2024), Armata Pharmaceuticals's total revenue was $966.00K, an increase of Infinity% from the same quarter last year. In Q1, Armata Pharmaceuticals's net income was $-25.02M. See Armata Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 5.92M$ 4.53M$ 5.51M$ 4.47M$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
$ 3.72M$ 4.53M----
Operating Expense
$ 44.47M$ 45.42M$ -42.45M$ -28.30M$ 21.59M$ 19.09M
Operating Income
$ -40.75M$ -40.89M$ -42.45M$ -28.30M$ -21.59M$ -19.09M
Net Non Operating Interest Income Expense
$ -4.21M$ -2.42M$ 29.00K$ -95.00K$ -600.00K$ -835.00K
Other Income Expense
$ 24.84M$ 21.18M$ -5.51M$ -5.20M$ 6.00K$ 445.00K
Pretax Income
$ -79.55M$ -69.02M$ -36.92M$ -23.19M$ -22.18M$ -19.48M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -79.58M$ -69.05M$ -36.92M$ -23.19M$ -22.18M$ -19.48M
Basic EPS
$ -2.20$ -1.91$ -1.08$ -0.96$ -1.35$ -2.49
Diluted EPS
$ -2.20$ -1.91$ -1.08$ -0.96$ -1.35$ -2.55
Basic Average Shares
$ 144.38M$ 36.08M$ 34.29M$ 24.10M$ 16.42M$ 7.83M
Diluted Average Shares
$ 144.38M$ 36.08M$ 34.29M$ 24.10M$ 16.42M$ 8.01M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 22.26M$ 45.42M$ -42.45M$ -28.30M$ 21.59M$ 19.09M
Net Income From Continuing And Discontinued Operation
$ -79.58M$ -69.05M$ -36.92M$ -23.19M$ -22.18M$ -19.48M
Normalized Income
$ -45.72M$ -32.68M--$ -22.18M$ -19.93M
Interest Expense
----$ 628.00K$ 931.00K
EBIT
$ -56.73M$ -66.42M$ -36.92M$ -23.09M$ -21.55M$ -18.55M
EBITDA
$ -55.90M$ -65.45M$ -36.02M$ -21.89M$ -20.44M$ -17.20M
Currency in USD

Armata Pharmaceuticals Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis